Company profile: Nuvectis Pharma
1.1 - Company Overview
Company description
- Provider of novel targeted cancer therapeutics, including NXP800, an oral small molecule activator of GCN2 in clinical trials for platinum-resistant, ARID1a-mutated ovarian cancer and cholangiocarcinoma, and NXP900, an oral small molecule inhibitor of SRC family kinases (SFK), including SRC and YES1, currently in a Phase 1 dose escalation clinical trial.
Products and services
- NXP900: Investigational oral small-molecule inhibits SRC Family of Kinases, including SRC and YES1, currently in a Phase 1 dose escalation clinical trial
- NXP800: Investigational oral small-molecule activates the kinase GCN2, in clinical trials for platinum-resistant, ARID1a-mutated ovarian cancer and cholangiocarcinoma
- Targeted Oncology Therapeutics Development: Clinical-stage biopharmaceutical program develops novel targeted therapeutics for the treatment of cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nuvectis Pharma
PCI Biotech
HQ: Norway
Website
- Description: Provider of photochemical drug delivery technologies for cancer therapy, focusing on photochemical internalisation (PCI) to enhance intracellular delivery of therapeutic compounds for novel cancer treatments, and photochemical lysis (PCL) to improve viral vector manufacturing through light-triggered cell lysis that increases yield and reduces impurities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PCI Biotech company profile →
Ultimovacs
HQ: Norway
Website
- Description: Provider of novel immunotherapies against cancer, including UV1, a peptide-based therapeutic cancer vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Offers TET vaccine adjuvant technology targeting antigen-presenting cells, and conducts clinical trials (INITIUM, NIPU, DOVACC, FOCUS) evaluating UV1 with checkpoint inhibitors across melanoma, mesothelioma, ovarian, and head and neck cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultimovacs company profile →
Capintec
HQ: United States
Website
- Description: Provider of calibration and measurement technologies for nuclear medicine applications, offering advanced technology and services with a commitment to continuous quality improvement, including the Captus® 4000e Thyroid Uptake System for measuring thyroid uptake.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Capintec company profile →
Exousia Pro
HQ: United States
Website
- Description: Provider of exosome-based therapeutics for cancer and other diseases, with research in plant-derived exosomes and integration of AI to support development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exousia Pro company profile →
EMulate Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic devices using proprietary ultra-low radio frequency energy (ulRFE) to elicit therapeutic biological effects. Programs include clinical testing in brain cancer and preclinical work in pain and mental health, advanced by subsidiaries: Cellsana (oncology; Phase III prep for glioblastoma/diffuse midline glioma), Mensana (mental health; Phase I prep), and Indolor (pain; Phase I prep).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EMulate Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nuvectis Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nuvectis Pharma
2.2 - Growth funds investing in similar companies to Nuvectis Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nuvectis Pharma
4.2 - Public trading comparable groups for Nuvectis Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →